Search the Newsreel

BOS Better Online Solutions Ltd (BOSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of BOS Better Online Solutions Ltd (BOSC), highlighting its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is described as trading between a resistance level of $4.63 and a support …

Competitive Pressure Bears Down on Boston Scientific's Key Growth Drivers

Boston Scientific has faced competitive pressure in its key growth areas, despite a strong history of innovation and operational efficiency. Under CEO Michael Mahoney, the company has focused on novel technology and accelerating growth. The article suggests that competitive forces are impacting the medical …

BOSC|BOS Better Online Solutions Ltd|Price:4.500|

This article provides a comprehensive stock analysis of BOS Better Online Solutions Ltd (BOSC), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within its industry. It notes strong institutional ownership, recent "Buy" ratings from analysts with a target price of …

Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company …

BOS Better Online Solutions Ltd (BOSC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for BOS Better Online Solutions Ltd (BOSC), highlighting its risk score, industry ranking, and beta value. It covers various volatility metrics, return performance over different periods, and liquidity indicators. The report suggests BOSC tends to outperform in …

Boston Scientific Corporation Q2 2026 Earnings Call Summary

Boston Scientific Corporation Q2 2026 Earnings Call Summary - Moby Performance Attribution and Strategic Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Boston Scientific again cuts 2026 guidance

Boston Scientific has cut its 2026 sales and earnings per share guidance for the second consecutive quarter, citing struggles in its electrophysiology and Watchman businesses. CEO Mike Mahoney stated that market conditions have evolved quickly, making forecasting challenging, and the company expects Watchman growth …

Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ...

This article first appeared on GuruFocus. Organic Sales Growth: 7% in Q2 2026, driven by Interventional Cardiology, Endoscopy, and Neuromodulation. Adjusted EPS: $0.86, a 15% increase, exceeding guidance range of $0.82 to $0.84. Adjusted Operating Margin: 28.4% in Q2 2026. Full Year 2026 Organic …

Boston Scientific revenue outlook drops, layoffs expected

Boston Scientific Corp. (Nasdaq: BSX) is reducing its 2026 revenue outlook for the second time, lowering it to 5%-6% from an initial 10%-11%. This comes as the company faces challenges with key revenue drivers. In response, Boston Scientific plans to cut jobs in Houston …

Boston Scientific beats second quarter expectations, raises full-year outlook

Boston Scientific beats second quarter expectations, raises full-year outlook Proactive uses images sourced from Shutterstock Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted …

'Not the outcome we planned:' Boston Scientific revenue outlook drops

Boston Scientific has lowered its revenue outlook, citing rapidly evolving market conditions and increased competition in its cardiovascular business, particularly in pulsed field ablation and heart devices. CEO Michael F. Mahoney acknowledged the challenge in forecasting effectively. The company is implementing a restructuring plan …

Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook

Boston Scientific has reported Q2 revenues of around $5.4bn, indicative of a 7.5% year-over-year (YoY) rise, yet has elected to trim its full-year outlook. The lion's share of Boston's revenues came from its cardiovascular segment at around $3.6bn, indicative of an 8.3% YoY uplift …

Boston Scientific Cuts Forecast on Product Slowdown and Competition

Boston Scientific (NYSE: BSX) has cut its fiscal 2026 outlook due to a slowdown in the U.S. Watchman heart implant market and increased competition in the EP market, causing its stock to trade lower. Despite beating Q2 revenue and adjusted earnings estimates, the company …

Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Boston Scientific (BSX) reported revenue of $5.44 billion, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Boston Scientific Cuts View on Unexpected Watchman Heart Implant Challenges

Boston Scientific lowered its full-year sales outlook due to unexpected challenges with two core heart-disease products. The company's Watchman heart implant experienced a sharp and unexpected slowdown in revenue, and its electrophysiology business is struggling against increased competition. This adjustment follows the release of …

Govt informed of potential job cuts at Boston Scientific

Medical device manufacturer Boston Scientific has informed the Irish Government of potential job cuts at its Irish operations, following the approval of a global restructuring plan aimed at cutting costs. The Department of Enterprise received a collective redundancy notification, indicating 30 or more potential …

Boston Scientific announces results for second quarter 2026

Boston Scientific (NYSE: BSX) reported solid second-quarter 2026 results, with net sales reaching $5.442 billion, a 7.5% increase year-over-year. The company's GAAP EPS was $0.61, and adjusted EPS hit $0.86, surpassing guidance. Key achievements included strategic investments, advancements in cardiovascular and orthopedic solutions with …

Boston Scientific Q2 2026 earnings: profit forecast cut on Watchman slowdown

Boston Scientific (BSX) beat second-quarter earnings expectations but cut its full-year profit forecast due to slower-than-expected demand for its Watchman heart implant. The company now projects adjusted EPS between $3.28 and $3.32, down from its previous guidance. This reduction is attributed to changing clinical …

Boston Scientific stock slips as outlook disappoints (BSX:NYSE)

Boston Scientific (BSX) stock fell by nearly 6% in premarket trading despite reporting better-than-expected Q2 2026 financials. The decline was triggered by the medical device maker setting its Q3 and full-year earnings outlook below analysts’ estimates. The Massachusetts-based company reported $5.4 billion in revenue.

Boston Scientific Beats Second-Quarter Expectations as Sales Growth Lifts Shares

Woman looking through microscope ©The U.S. National Archives Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The …

Boston Scientific Corporation gibt Ergebnisprognose für das dritte Quartal und das Gesamtjahr 2026 ab

Boston Scientific trims annual profit forecast on softer Watchman device demand

July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart ‌device business. The company, in May, warned of pressure on its ‌Watchman heart device, a small implant used to help prevent stroke-causing …

Boston Scientific stock gains as medical device maker tops Q2 forecasts

Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates. The company posted second-quarter earnings per share of $0.86, beating the analyst estimate of $0.83. Revenue …

Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations

Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 7.5% year on year to $5.44 billion. On the other hand, …

Boston Scientific Q2 26 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Boston Scientific Corp (BSX) will host a conference call at 8:00 AM ET on July 29, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://investors.bostonscientific.com/events-and-presentations The views and opinions expressed herein are the views and …

Boston Scientific (NYSE:BSX) shares fall as international growth offsets slower U.S. cardiac performance

Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates

Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs

BSX|Boston Scientific Corp|Kurs:49.310|Änderung %:+0.015

The 5 Most Interesting Analyst Questions From Boston Beer’s Q2 Earnings Call

Boston Pizza Royalties Q2 Results: Aug 13 Earnings Date Set

BOSTON PIZZA ROYALTIES INCOME FUND AND BOSTON PIZZA INTERNATIONAL INC. TO ANNOUNCE 2026 SECOND QUARTER RESULTS ON AUGUST 13TH

Mike Ashley’s Frasers Group Takes 4.2% Stake in Burberry

Busy Bee: Mike Ashley's Frasers Group is all over lately. Frasers, which made a surprise takeover bid for Hugo Boss last month, said in a regulatory filing that it had amassed put options on 15 million shares of Burberry Group, giving it a 4.2 …

PATENT—Fed. Cir.: Court reverses University of Texas patent victory against Boston Scientific

The Federal Circuit has reversed a patent victory obtained by the University of Texas against Boston Scientific. This decision impacts a legal dispute concerning patent infringement.

Boston Scientific plans job cuts in global restructuring

Boston Scientific is implementing a global restructuring plan that will result in job cuts. The medical device company's decision was announced as part of an effort to streamline operations and adapt to changing market conditions. Details regarding the number of affected employees and specific …

Boston Scientific Corp. stock underperforms Tuesday when compared to competitors despite daily gains

Boston Scientific Corp. (BSX) stock rose 1.21% on Tuesday, closing at $46.06. Despite this gain, the stock underperformed compared to the broader market, as the S&P 500 Index and Dow Jones Industrial Average both saw larger increases. This marks the fourth consecutive day of …